Ghrelin, obesity and diabetes

Petra Wiedmer; Rubén Nogueiras; Fabio Broglio; David D'Alessio; Matthias H. Tschöp

doi:10.1038/ncpendmet0625

Ghrelin, obesity and diabetes

Petra Wiedmer, Rubén Nogueiras, Fabio Broglio, David D'Alessio, Matthias H. Tschöp

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Abstract

The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.

Original language	English
Pages (from-to)	705-712
Number of pages	8
Journal	Nature Clinical Practice Endocrinology and Metabolism
Volume	3
Issue number	10
DOIs	https://doi.org/10.1038/ncpendmet0625
State	Published - Oct 2007
Externally published	Yes

Keywords

Diabetes
Ghrelin
Metabolic syndrome
Obesity
Obestatin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ncpendmet0625

Cite this

@article{b72b6faa79e0405ca04160ac9add70db,

title = "Ghrelin, obesity and diabetes",

abstract = "The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.",

keywords = "Diabetes, Ghrelin, Metabolic syndrome, Obesity, Obestatin",

author = "Petra Wiedmer and Rub{\'e}n Nogueiras and Fabio Broglio and David D'Alessio and Tsch{\"o}p, {Matthias H.}",

year = "2007",

month = oct,

doi = "10.1038/ncpendmet0625",

language = "English",

volume = "3",

pages = "705--712",

journal = "Nature Clinical Practice Endocrinology and Metabolism",

issn = "1745-8366",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Ghrelin, obesity and diabetes

AU - Wiedmer, Petra

AU - Nogueiras, Rubén

AU - Broglio, Fabio

AU - D'Alessio, David

AU - Tschöp, Matthias H.

PY - 2007/10

Y1 - 2007/10

N2 - The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.

AB - The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.

KW - Diabetes

KW - Ghrelin

KW - Metabolic syndrome

KW - Obesity

KW - Obestatin

UR - http://www.scopus.com/inward/record.url?scp=34648821994&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0625

DO - 10.1038/ncpendmet0625

M3 - Review article

C2 - 17893689

AN - SCOPUS:34648821994

SN - 1745-8366

VL - 3

SP - 705

EP - 712

JO - Nature Clinical Practice Endocrinology and Metabolism

JF - Nature Clinical Practice Endocrinology and Metabolism

IS - 10

ER -

Ghrelin, obesity and diabetes

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this